Overview
- Pfizer completed the acquisition for $65.60 per share in cash plus up to $20.65 per share in contingent value rights, valuing the deal at as much as about $10 billion, and Metsera is now a wholly owned subsidiary with its Nasdaq listing ending.
- Metsera said the FTC warned its board about antitrust risks in Novo Nordisk’s two‑step offer, after which Novo withdrew from the contest.
- The deal adds MET‑097i, a weekly or monthly injectable GLP‑1 nearing Phase 3, MET‑233i, a monthly amylin analog in early studies, and an oral GLP‑1 candidate.
- Pfizer said the transaction will be dilutive through 2030 as it funds development, and CEO Albert Bourla has indicated potential first launches in 2028 if trials succeed.
- Shareholders approved Pfizer’s sweetened proposal, concluding a fast‑escalating series of competing bids from Novo that included an unconventional partial‑control structure.